2. Academic Validation
  3. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

  • Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. doi: 10.1016/S2352-4642(22)00239-5.
Esmée C de Baat 1,  Elvira C van Dalen 2,  Renée L Mulder 2,  Melissa M Hudson 3,  Matthew J Ehrhardt 3,  Frederike K Engels 2,  Elizabeth A M Feijen 2,  Heynric B Grotenhuis 4,  Jan M Leerink 5,  Livia Kapusta 6,  Gertjan J L Kaspers 7,  Remy Merkx 8,  Luc Mertens 9,  Roderick Skinner 10,  Wim J E Tissing 2,  Florent de Vathaire 11,  Paul C Nathan 9,  Leontien C M Kremer 12,  Annelies M C Mavinkurve-Groothuis 2,  Saro Armenian 13
Affiliations

Affiliations

  • 1 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Electronic address: e.c.debaat-2@prinsesmaximacentrum.nl.
  • 2 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • 3 Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • 4 Department of Pediatric Cardiology, Utrecht, Netherlands.
  • 5 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • 6 Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, Netherlands; Pediatric Cardiology Unit, Department of Pediatrics, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Centre affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 7 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Netherlands.
  • 8 Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands.
  • 9 The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • 10 Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
  • 11 Gustave Roussy Institute, Paris, France.
  • 12 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Wilhelmina Children's Hospital-University Medical Center Utrecht, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Netherlands.
  • 13 Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA.
PMID: 36174614 DOI: 10.1016/S2352-4642(22)00239-5
Abstract

Survivors of childhood Cancer are at risk of anthracycline-induced cardiotoxicity, which might be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane, and little guidance is available on its use in children. To facilitate global consensus, a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the existing literature and used evidence-based methodology to develop a guideline for dexrazoxane administration in children with Cancer who are expected to receive anthracyclines. Recommendations were made in consideration of evidence supporting the balance of potential benefits and harms, and clinical judgement by the expert panel. Given the dose-dependent risk of anthracycline-induced cardiotoxicity, we concluded that the benefits of dexrazoxane probably outweigh the risk of subsequent neoplasms when the cumulative doxorubicin or equivalent dose is at least 250 mg/m2 (moderate recommendation). No recommendation could be formulated for cumulative doxorubicin or equivalent doses of lower than 250 mg/m2, due to insufficient evidence to determine whether the risk of cardiotoxicity outweighs the possible risk of subsequent neoplasms. Further research is encouraged to determine the long-term efficacy and safety of dexrazoxane in children with Cancer.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z